Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas.
Recurrences of Hodgkin's Lymphoma (HL) 5 years after the initial therapy are rare. The aim of this study is to report a single centre experience of the clinical characteristics, outcome, and toxicity of pts who experienced very late relapses, defined as relapses that occurred 5 or more years after the achievement of first complete remission. Of 532 consecutive pts with classical HL treated at our Institute from 1985 to 1999, 452 pts (85%) achieved a complete remission. Relapse occurred in 151 pts: 135 (29.8%) within 5 years and 16 over 5 years (3.5%, very late relapses). Very late relapses occurred after a median disease-free interval of 7 years (range: 5-18). Salvage treatment induced complete remission in 14 pts (87.5%). At a median of 4 years after therapy for very late relapse, 10 pts (63%) are still alive and free of disease and 6 (37%) died (1 from progressive HL, 1 from cardiac disease, 1 from thromboembolic disease, 1 from HCV reactivation, and 2 from bacterial infection). The probability of failure-free survival at 5 years was 75%. The majority of deaths are due to treatment-related complications. Therapy regimens for very late relapse HL are warranted to minimize complications.
Hematology Department, DAP, University of Bari, Piazza G.Cesare 11, 70124 Bari, Italy.
Francesco
F
Gaudio
Annamaria
A
Giordano
Vincenzo
V
Pavone
Tommasina
T
Perrone
Paola
P
Curci
Domenico
D
Pastore
Mario
M
Delia
Clara
C
De' Risi
Alessandro
A
Spina
Vincenzo
V
Liso
Giorgina
G
Specchia
Cancer. 1997 Sep 15;80(6):1124-33
9305714
J Clin Oncol. 1999 Apr;17(4):1244
10561185
Haematologica. 2001 Mar;86(3):274-81
11255274
Eur J Haematol. 2003 Nov;71(5):327-33
14667195
Blood. 2000 Aug 15;96(4):1280-6
10942369
J Clin Epidemiol. 2008 Apr;61(4):344-9
18313558
Indian J Cancer. 1990 Mar;27(1):17-9
2391126
Cancer. 1997 Apr 1;79(7):1422-7
9083165
Isr Med Assoc J. 2004 Feb;6(2):112-3
14986471
Leuk Lymphoma. 1997 Jun;26(1-2):121-5
9250796
Ann Oncol. 2004 Dec;15(12):1798-804
15550585
Clin Oncol (R Coll Radiol). 1993;5(6):399
8305367
Curr Opin Oncol. 2000 Sep;12(5):403-11
10975546
Ann Hematol. 2000 Mar;79(3):110-3
10803931
Dtsch Med Wochenschr. 1994 Apr 8;119(14):536
8156888
Blood. 1994 Oct 15;84(8):2447-51
7919364
J Clin Oncol. 2003 Feb 15;21(4):607-14
12586796
Am J Med. 1971 Aug;51(2):222-40
5315323
Acta Haematol. 1992;87(3):122-5
1642092
Ann Intern Med. 1982 Feb;96(2):139-43
6174060
J Clin Oncol. 1993 Feb;11(2):225-32
8426198
Presse Med. 1988 Mar 12;17(9):423-7
2966382
Ann Oncol. 1993 Nov;4(9):767-73
8280658
Am J Hematol. 1981;10(1):31-6
7258180
Cancer. 1998 Aug 1;83(3):560-5
9690550
Leuk Lymphoma. 1997 Dec;28(1-2):215-7
9498723
Ann Intern Med. 1985 Mar;102(3):292-7
3970468
Oncology. 1995 Jul-Aug;52(4):284-6
7777240
Am J Clin Oncol. 2001 Dec;24(6):576-8
11801757
J Clin Oncol. 1983 Jul;1(7):432-9
6199478
N Engl J Med. 1998 Nov 19;339(21):1506-14
9819449
Blood. 1997 Feb 1;89(3):814-22
9028312
Haematologica. 1992 Sep-Oct;77(5):435-7
1483597
J Pathol. 1991 Aug;164(4):291-7
1656004
Med Oncol. 2000 Feb;17(1):59-63
10713662
Blood. 2004 Dec 1;104(12):3483-9
15315964
Blood. 1998 Apr 15;91(8):3011-6
9531614